Skip to search formSkip to main contentSkip to account menu

How Important Treatment Based on Tumor Molecular Profile Improves Symptoms

Known as: Improves symptoms (e.g., reduces pain, increases appetite) 
A question about how an individual rates the importance that treatment based on the molecular profile of their specific tumor improves symptoms.
National Institutes of Health

Related topics

Related topics

1 relation
Attitudes and Preferences Questionnaire

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2019
Review
2019
Astym® therapy improves FOTO® outcomes for patients with musculoskeletal disorders: an observational study.
Background Current healthcare providers function in an environment where there is increased emphasis on value-based models of… 
2018
2018
Clodronate improves lameness in horses without changing bone turnover markers
BACKGROUND Clodronate is prescribed to performance horses with lameness. Despite its clinical popularity, little research has… 
2018
2018
Clodronate Improves Lameness in Horses Independent of Anti-Resorptive Effects In Vivo
Review
2016
Review
2016
Обоснование применения и преимущества триметазидина при сердечной недостаточности, обусловленные его влиянием на метаболизм миокарда
Heart failure (HF) is systemic and multiple organ syndrome, with metabolic insufficiency as one of its main causes. Heart… 
Highly Cited
2016
Highly Cited
2016
High-volume plasma exchange in patients with acute liver failure: An open randomised controlled trial.
2015
2015
[Acute skin toxicity in breast intensity modulated radiotherapy using field in field technique].
2015
2015
Evidence-Based Parenting Training of Foster Parents Improves Empathy and Skills
2013
2013
The Team-based learning improves students’ performances at the Undergraduate Nursing Course.
Highly Cited
2011
Highly Cited
2011
Erlotinib versus chemotherapy (CT) in advanced non-small cell lung cancer (NSCLC) patients (p) with epidermal growth factor receptor (EGFR) mutations: Interim results of the European Erlotinib Versus…
7503 Background: EGFR tyrosine kinase activating mutations are present in 10-26% of NSCLC tumors and are associated with… 
2010
2010
Abstract P5-10-05: A Phase III Adjuvant Randomized Trial of 6 Cycles of 5-Fluorouracil - Epirubicine-Cyclophosphamide (FEC100) Versus 4 FEC 100 Followed by 4 Taxol (FEC-T) in Node Positive Breast…
The risk of relapse after local therapy remains unacceptable for the majority of patients with early stage breast cancer… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)